Recent studies have started to investigate the use of multi-modal data in treatment response prediction for various cancers, including clear cell renal cell carcinoma,35 non-small cell lung cancer,17,36,37 and hepatocellular carcinoma.38 However, there is a notable scarcity of response prediction research on patients with HER2-positive GC and their response to anti-HER2 therapy. This evidence concerns the gene ERBB2 and hepatocellular carcinoma.